These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38479162)

  • 1. Participant experiences in a pilot study for methamphetamine withdrawal treatment: Implications for retention.
    Acheson LS; Clay S; McKetin R; Lintzeris N; Dunlop A; Brett J; Christmass M; Rodgers C; Shoptaw S; Farrell M; Ezard N; Siefried KJ
    Int J Drug Policy; 2024 Apr; 126():104383. PubMed ID: 38479162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: A pilot feasibility and safety trial.
    Acheson LS; Ezard N; Lintzeris N; Dunlop A; Brett J; Rodgers C; Gill A; Christmass M; McKetin R; Farrell M; Shoptaw S; Siefried KJ
    Drug Alcohol Depend; 2022 Dec; 241():109692. PubMed ID: 36399936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trial protocol of an open label pilot study of lisdexamfetamine for the treatment of acute methamphetamine withdrawal.
    Acheson LS; Ezard N; Lintzeris N; Dunlop A; Brett J; Rodgers C; Gill A; Christmass M; McKetin R; Farrell M; Shoptaw S; Siefried KJ
    PLoS One; 2022; 17(10):e0275371. PubMed ID: 36190973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot randomised controlled trial of modafinil during acute methamphetamine withdrawal: feasibility, tolerability and clinical outcomes.
    Lee N; Pennay A; Hester R; McKetin R; Nielsen S; Ferris J
    Drug Alcohol Rev; 2013 Jan; 32(1):88-95. PubMed ID: 22630616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of a controlled amphetamine withdrawal paradigm among adults who use methamphetamine: A pilot clinical trial.
    Thompson RG; Oliveto A; Thostenson JD; Wilson MP; McGaugh J; Mancino MJ
    J Psychopharmacol; 2021 Nov; 35(11):1420-1430. PubMed ID: 34697965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence.
    Ezard N; Dunlop A; Hall M; Ali R; McKetin R; Bruno R; Phung N; Carr A; White J; Clifford B; Liu Z; Shanahan M; Dolan K; Baker AL; Lintzeris N
    BMJ Open; 2018 Jul; 8(7):e020723. PubMed ID: 30030312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. People with lived and living experience of methamphetamine use and admission to hospital: what harm reduction do they suggest needs to be addressed?
    Forchuk C; Serrato J; Scott L
    Health Promot Chronic Dis Prev Can; 2023 Jun; 43(6):338-347. PubMed ID: 37466399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing the effect of buprenorphine and methadone in the reduction of methamphetamine craving: a randomized clinical trial.
    Ahmadi J; Razeghian Jahromi L
    Trials; 2017 Jun; 18(1):259. PubMed ID: 28587620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experiences in managing problematic crystal methamphetamine use and associated depression in gay men and HIV positive men: in-depth interviews with general practitioners in Sydney, Australia.
    Saltman DC; Newman CE; Mao L; Kippax SC; Kidd MR
    BMC Fam Pract; 2008 Aug; 9():45. PubMed ID: 18702829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal.
    Cruickshank CC; Montebello ME; Dyer KR; Quigley A; Blaszczyk J; Tomkins S; Shand D
    Drug Alcohol Rev; 2008 May; 27(3):326-33. PubMed ID: 18368615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility and acceptability of approach bias modification during methamphetamine withdrawal and related methamphetamine use outcomes.
    Manning V; Garfield JBB; Mroz K; Campbell SC; Piercy H; Staiger PK; Lum JAG; Lubman DI; Verdejo-Garcia A
    J Subst Abuse Treat; 2019 Nov; 106():12-18. PubMed ID: 31540606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts.
    Noorani T; Garcia-Romeu A; Swift TC; Griffiths RR; Johnson MW
    J Psychopharmacol; 2018 Jul; 32(7):756-769. PubMed ID: 29938565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experiences of Patients After Withdrawal From Cancer Clinical Trials.
    Ulrich CM; Knafl K; Foxwell AM; Zhou Q; Paidipati C; Tiller D; Ratcliffe SJ; Wallen GR; Richmond TS; Naylor M; Gordon TF; Grady C; Miller V
    JAMA Netw Open; 2021 Aug; 4(8):e2120052. PubMed ID: 34374772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Live to tell: Narratives of methamphetamine-using women taken hostage by their intimate partners in San Diego, CA.
    Ludwig-Barron N; Syvertsen JL; Lagare T; Palinkas LA; Stockman JK
    Int J Drug Policy; 2015 Sep; 26(9):843-50. PubMed ID: 26164713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of modafinil treatment on neuropsychological and attentional bias performance during 7-day inpatient withdrawal from methamphetamine dependence.
    Hester R; Lee N; Pennay A; Nielsen S; Ferris J
    Exp Clin Psychopharmacol; 2010 Dec; 18(6):489-97. PubMed ID: 21186923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized clinical trial on the effects of bupropion and buprenorphine on the reduction of methamphetamine craving.
    Ahmadi J; Sahraian A; Biuseh M
    Trials; 2019 Jul; 20(1):468. PubMed ID: 31362784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SMART Family and Friends: Feasibility and outcomes of a video-conference delivered intervention for families impacted by another's methamphetamine use.
    Rushton CM; Kelly PJ; Thomas T; Beck AK; Townsend C; Baker AL; Manning V; Argent A; Deane FP; Hides L; Hitsman B; Velleman R; Velleman G; Larance B
    J Subst Use Addict Treat; 2024 Jun; 161():209355. PubMed ID: 38548059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A qualitative study of methamphetamine users' perspectives on barriers and facilitators of drug abstinence.
    Herbeck DM; Brecht ML; Christou D; Lovinger K
    J Psychoactive Drugs; 2014; 46(3):215-25. PubMed ID: 25052880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterizing methamphetamine withdrawal in recently abstinent methamphetamine users: a pilot field study.
    Mancino MJ; Gentry BW; Feldman Z; Mendelson J; Oliveto A
    Am J Drug Alcohol Abuse; 2011 Mar; 37(2):131-6. PubMed ID: 21219261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association between interleukin-8 levels and the development of withdrawal symptoms during methamphetamine abstinence.
    Feng L; He W; Lin S; Ruan Y; Yuan C; Qiu H; Ren W; He J
    Hum Psychopharmacol; 2020 Jul; 35(4):e2736. PubMed ID: 32352600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.